BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px
Document › Details

Expression Pathology Inc.. (2/13/12). "Press Release: Expression Pathology Collaborates on Liquid Tissue Personalized Medicine Assays in Lung Cancer Treatment". Rockville, MD.

Region Region United States (USA)
Organisations Organisation Expression Pathology Inc. (EPI)
  Today OncoPlex Diagnostics (OncoPlexDx)
  Group OncoPlex Diagnostics (OncoPlexDx)
  Organisation 2 M. D. Anderson Cancer Center
  Group University of Texas System
Products Product Liquid Tissue Array
  Product 2 Liquid Tissue® technology (Expression Pathology)
Person Person Tunon, Peter (Expression Pathology 200501– VP Sales + Marketing)

Expression Pathology Inc. a leader in personalized medicine tissue protein analysis, today announced a collaboration with The University of Texas MD Anderson Cancer Center to evaluate the use of the company's tests for matching the most appropriate targeted therapies with lung cancer patients. The research will study the company's patented Liquid Tissue®-SRM technology, which enables accurate measurement of proteins in tumor pathways.

Lung cancer is the leading cause of cancer-related deaths worldwide. In the United States alone, there were an estimated 226,160 new cases and 160,340 deaths in 2012, with lung cancer accounting for 15% of cancer diagnoses but 28% of cancer deaths (American Cancer Society, Cancer Facts & Figures 2012).

A new generation of lung cancer drugs that target specific tumor pathways is having a significant positive impact on treatment, but improved testing methods are needed to help guide drug selection. The advantage of Expression Pathology's Liquid Tissue® SRM technology is the unique ability to quantify - in a single assay - multiple proteins involved in tumor pathways, in formalin-fixed paraffin-embedded (FFPE) tissue, the standard form of tissue preservation employed in medical practice worldwide.

About Expression Pathology

Expression Pathology Inc. is a private biotechnology company focused on advancing personalized medicine with tumor tests that improve cancer treatment decisions while reducing health care costs. The company has translated its patented Liquid Tissue® SRM technology platform into a pipeline of innovative cancer pathway tests that have entered clinical studies with top tier cancer treatment centers and are being used by pharmaceutical companies in development of new cancer drugs.

The company's tests employ a mass spectrometry technique called Selected Reaction Monitoring (SRM) which can simultaneously and quantitatively measure many proteins at a time. Liquid Tissue® SRM methodology and tests are covered by four issued and 28 pending U.S. and international patents.

For more information, please visit

For more information please contact:

Peter Tunon
VP Sales and Marketing
Expression Pathology Inc.
9620 Medical Center Drive
Rockville, MD 20850

Record changed: 2016-03-19


Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px

More documents for OncoPlex Diagnostics (OncoPlexDx)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px